Effect of Marihuana on Intraocular and Blood Pressure in Glaucoma

Author: John C.Merritt MD, William J.Crawford PhD, Paul C.Alexander MD, Alfred L.Anduze MD, Solomon S.Gelbart MD Published in Science Direct March 1980 Abstract Marihuana inhalation was accompanied by increased heart rate and decreased intraocular and blood pressure in 18 subjects with heterogenous glaucomas. The hypotensive effects appeared in 60 to 90 minutes as the decrease in…

Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration

Author: I. Matias, J.W. Wang, A. Schiano Moriello, A. Nieves, D.F. Woodward,V. Di Marzo Published in Science Direct December 2006 Abstract Cannabinoid receptors and the endocannabinoids (anandamide (N-arachidonoylethanolamine—AEA) and 2-arachidonoylglycerol (2-AG)), as well as the AEA congener, palmitoylethanolamide (PEA), are involved in ocular physiology. We measured endocannabinoid and PEA levels by isotope-dilution liquid chromatography-mass spectrometric analysis…

Cannabis and glaucoma: A literature review

Author: Kathleen MacMillan MacMillan, Amanda Keddy, James Furlon Published in Dalhousie Medical Journal  2019 Abstract Introduction: Primary open-angle glaucoma (POAG) is characterized by the loss of retinal ganglion cells secondary to optic neuropathy; increased intraocular pressure (IOP) may or may not be present. Many treatment options focus on decreasing IOP measurements to attempt to prevent progression…

Diurnal and 24-h Intraocular Pressures in Glaucoma: Monitoring Strategies and Impact on Prognosis and Treatment

Author: Anastasios G. Konstas, Malik Y. Kahook, Makoto Araie, Andreas Katsanos, Luciano Quaranta, Luca Rossetti, Gábor Holló, Efstathios T. Detorakis, Francesco Oddone, Dimitrios G. Mikropoulos & Gordon N. Dutton Published in Springer Link  October 2008 Abstract The present review casts a critical eye on intraocular pressure (IOP) monitoring and its value in current and future glaucoma…

Experiences with Administration of Marihuana to Glaucoma Patients

Author: Robert S. HeplerRobert J. Petrus Published in Springer Link  1976 Abstract In 1971 Hepler and Frank reported reduction in intraocular pressure occurring after healthy young adults smoked marihuana. These initial observations led to additional studies designed to compare the pressure-reducing effects of placebo, smoked marihuana, and injected THC. Consistent, statistically-significant pressure reduction was observed in…

Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol

Author: Brenda K.Colasanti, Charles R. Craig, R. David Allara Published in Science Direct September 1984 Abstract Cannabinol or cannabigerol was administered to cats topically in doses of 250, 500 and 1000 μg as a single drop or chronically via osmotic minipumps (20 μg hr−1) over a period of 9 days. While cannabinol had a modest…

Finding of endocannabinoids in human eye tissues: Implications for glaucoma

Author: June Chen, Isabel Matias, Tim Dinh, Ta Lu, Sonia Venezia, Amelia Nieves, David F. Woodward, Vincenzo Di Marzo Published in Science Direct May 2005 Abstract Cannabinoid CB1 receptors are involved in ocular physiology and may regulate intraocular pressure (IOP). However, endocannabinoid levels in human ocular tissues of cornea, iris, ciliary body, retina, and choroid from…

The Endocannabinoid System as a Therapeutic Target in Glaucoma

Author: Elizabeth A. Cairns,1 William H. Baldridge,2,3 and Melanie E. M. Kelly Published in Hindawi January 2016 Abstract Glaucoma is an irreversible blinding eye disease which produces progressive retinal ganglion cell (RGC) loss. Intraocular pressure (IOP) is currently the only modifiable risk factor, and lowering IOP results in reduced risk of progression of the disorder. The…

Δ9‐Tetrahydrocannabinolic acid alleviates collagen‐induced arthritis: Role of PPARγ and CB1 receptors

Author: Belén Palomares Martín Garrido‐Rodriguez Claudia Gonzalo‐Consuegra María Gómez‐Cañas Suwipa Saen‐oon Robert Soliva Juan A. Collado Javier Fernández‐Ruiz Gaetano Morello Marco A. Calzado Giovanni Appendino Eduardo Muñoz Published in British Pharmacological Society  June 2020 Abstract Background and Purpose Δ9‐Tetrahydrocannabinolic acid (Δ9‐THCA‐A), the precursor of Δ9‐THC, is a non‐psychotropic phytocannabinoid that shows PPARγ agonist activity. Here, we investigated…

A national survey of US emergency medicine physicians on their knowledge regarding state and federal cannabis laws.

Author: Kevin M. Takakuwa, Frances S. Shofer, and Raquel M. Schears. Published in Mary Ann Liebert, Inc, Publishers February 2020 Abstract Introduction Medical cannabis laws have been passed in 33 U S States but cannabis remains federally illegal Eleven states additionally allow for adult use recreational Studies report and increase in Emergency Department ED use when…

The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage

Author: Kevin M. Takakuwa, Jeffrey Y. Hergenrather, Frances S. Shofer, and Raquel M. Schears Published in Mary Ann Liebert, Inc. Publishers January 2020 Abstract Objectives: To determine if cannabis may be used as an alternative or adjunct treatment for intermittent and chronic prescription opioid users. Design: Retrospective cohort study. Setting: A single-center cannabis medical practice site…

What is Exo-THC?

Dr. Patricia Frye, SCC Board Member and Director of Takoma Park Integrative Care, asks Christopher Hudalla, Ph. D. of Proverde Labs about Exo-THC.